Core One Labs Inc. Provides Clarification on Terms of Definitive Agreement to Acquire Micro-Cultivation Facility in Canada

VANCOUVER, British Columbia, Nov. 5, 2019 /CNW/ -- Core One Labs Inc. COOL, CLABF, (Frankfurt: LD6, WKN: A14XHT) ("COOL" or the "Company") is issuing this news release to clarify the terms of its definitive agreement to acquire Rainy Daze Cannabis, which was announced on November 4, 2019. 

The Company has entered into a definitive agreement to acquire all of the issued and outstanding shares of 1210950 B.C. Ltd., an arms-length company operating as "Rainy Daze Cannabis" ("Rainy Daze").  To acquire Rainy Daze, the Company has agreed to pay $100,000 in cash to the current shareholders of Rainy Daze, and to issue an aggregate of 3,500,000 common shares of the Company. The shares to be issued to the current shareholders of Rainy Daze are not expected to be subject to restrictions on transfer upon their issuance. 

Closing of the acquisition of Rainy Daze is subject to the approval of the Company's directors.  The Company's directors are currently conducting additional due diligence investigations with respect to the proposed acquisition.

About CannaStrips^TM

CannaStrips^TM is a formulated oral strip for effective buccal mucosal delivery that disrupts the barrier created by saliva coating the mucosal membrane for the active materials (in this case cannabinoids) which have been nanoparticulated and encapsulated to penetrate the multiple layers of mucosal and sub-mucosal membranes to the blood stream.  Once in the blood stream the encapsulation is undetectable as a foreign material by the liver. This undetectability allows the material to avoid being filtered out of the blood stream by the liver. The encapsulation also is more effective in penetrating the blood-brain barrier and allowing for greater bioavailability and extending the effective time from a single dose.

About Core One Labs Inc.

Core One Labs Inc. is a technology company that licenses its technology to a state-of-the-art production and packaging facility located in Southern California. The Company's technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to other forms of delivery but also superior bioavailability of cannabis constituents. Some strips will also include supplemental co-active ingredients such as nutraceuticals, vitamins and peptides. The technology provides a new way to accurately meter the dosage and assure the purity of selected product.  From start to finish, the production process, based on the Company's technology, tests for quality and composition of all the ingredients used in each and every strip which results in a delivery system that is safe, consistent and effective. In addition, through its efforts to develop a better CannaStripsTM product, the Company has developed considerable expertise in cannabis extraction and nursery activities.  The operational expertise developed by the Company as a result of these efforts has created new market opportunities for the Company in white label sales.

Core One Labs Inc.
Brad Eckenweiler
CEO & Director

FOR MORE INFORMATION, PLEASE CONTACT:
InvestorRelations@coreonelabs.ca
1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970.  Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, The Company undertakes no obligation to publicly update or revise forward-looking information.

SOURCE Core One Labs Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2019/05/c9483.html